About this Course
Kidney transplantation is an advancing field and has become a treatment of choice for patients with end stage renal disease as it provides a better quality of life to these patients. This curriculum will be delivered through online lectures and aims to provide the clinicians knowledge and competencies for the successful clinical evaluation and to provide the standard of care in the best interest of their patients. This online program is presented in association with Mayo Clinic and their experts shall provide a comprehensive update on various aspects of kidney transplantation.
Objective of the Course
The objectives of this course are:
- Evaluate potential transplant candidate and living donors
- Review the immunologic basis for rejection
- Understand the different immunosuppressive medication regimen and options in transplant recipient
- Discuss outcomes for transplant recipient
- Discuss outcomes for living donor
- Review infectious complications in transplant recipient
Need for the Course
Meet the Faculty
Dr. Girish MourM.B.B.S., M.D.
Dr. Girish Mour is an Assistant Professor of Medicine at Mayo Clinic, Arizona. He graduated from University of Pittsburgh Medical Center in 2014. His research interests include frailty, Elderly transplantation and health care disparities. He also participates in a number of clinical trials in kidney transplantation.
Dr. Justin D. KreuterM.D.
Dr. Justin Kreuter is an assistant professor of laboratory medicine & pathology as well as associate director of the histocompatibility laboratory at Mayo Clinic in Rochester, Minnesota.
Dr. Carrie SchinstockM.D.
Dr. Carrie Schinstock is an Associate Professor in the Division of Nephrology and Hypertension at Mayo Clinic in Rochester, MN where she is the Medication Director of the Kidney Transplant program and Convergence Chair for the 3 Mayo Clinic Transplant programs in Minnesota, Arizona, and Florida. She also serves as a chair on the Banff Antibody Mediated Rejection Working Group and participates in the STAR working group through AST. Her clinical and research expertise is in antibody mediated rejection and kidney paired donation. She has particular expertise in getting patients transplanted with high levels of alloantibody towards their donor including HLA incompatible transplantation and desensitization strategies. She also has interest in therapeutic clinical trials for patients with chronic antibody mediated rejection.
Rebecca CoreyPharm.D., R.Ph., BCPS
Rebecca Corey received her Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy. After graduation, she completed an ASHP accredited Pharmacy Practice Residency followed by a Solid Organ Transplant Specialty Residency at the University of Rochester Medical Center in Rochester, New York. Since completion of her residency training, Dr. Corey has been employed as a Clinical Pharmacy Specialist at several renowned transplant centers including the Thomas E. Starzl Transplant Institute at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, Cleveland Clinic in Cleveland, Ohio and Mayo Clinic in Phoenix, Arizona. Throughout her career, Dr. Corey has taught and mentored numerous pharmacy students and residents as well as many other healthcare providers. In addition, she has authored or co-authored research articles, reviews and book chapters and she has been an invited speaker and presented research abstracts at local, national and international scientific meetings. Dr. Corey is a Board Certified Pharmacotherapy Specialist and an Assistant Professor of Medicine in the Mayo Clinic College of Medicine. She has dedicated her career to the clinical care of many different types of transplant recipients and is passionate about helping patients both before and after organ transplantation. Dr. Corey is currently employed as a Clinical Pharmacy Specialist for the Liver, Kidney and Pancreas Transplant programs at Mayo Clinic in Phoenix, Arizona.
Dr. Martin MaiM.D. FACP
Dr. Martin Mai joined the Kidney/Pancreas Transplant team at Mayo Clinic Florida in October 2001. He was trained under Dr. Tom Gonwa and worked for 13 years as a transplant nephrologist at Baylor University Medical Center in Dallas, Texas before coming to Mayo Clinic. While in Dallas, he worked as the Co-Director of Pretransplant at Baylor University Medical Center, Medical Director of a 150 patient dialysis center in Dallas, and Vice-President of Dallas Nephrology Associates. Training includes: -Fellowship, Nephrology, Baylor University Medical Center, Dallas, TX -Residency, Internal Medicine, Baylor University Medical Center, Dallas, TX -MD, University of Texas-Southwestern Medical Center, Dallas, TX -BS, Chemical Engineering, University of Notre Dame, South Bend, IN -Board Certified in Critical Care Medicine, 1991 and 2001 -Board Certified in Nephrology, 1988 -Board Certified in Internal Medicine, 1986 He is the Medical Director of Kidney Transplant, Chair Division of Transplant Medicine and Associate Program Director for the General Nephrology fellowship. Research interests include immunosuppression in kidney transplant, paired kidney donation, renal disease in liver transplant and high-risk kidney transplantation. He enjoys giving talks to patient groups, nurses and physicians and is a board member of Gabriel House of Care.
Dr. Hasan KhamashM.D., Assistant Professor of Medicine
Dr. Hasan Khamash is a transplant nephrologist at Mayo Clinic in Phoenix/Scottsdale, Arizona. His areas of clinical expertise include kidney paired donation, antibody mediated rejection and desensitization, BK virus (BKV) nephropathy, and kidney transplant outcomes. In addition to a busy clinical practice, Dr. Khamash is an active participant in research and medical education and is the medical director of the kidney transplant program.
Dr. Juan Banacloche
Dr. Banacloche received his medical education at the Universidad Autónoma Medical School in Madrid, Spain. He came to the NIH, where he obtained Allergy and Immunology and Infectious Diseases fellowships at Dr. Anthony Fauci’s Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), under the mentorship of Dr. H. Clifford Lane. His research focused on immune reconstitution in HIV infection and HIV-specific T-cell responses. In the year 2000 he joined the National Cancer Institute (NCI) as Infectious Diseases Consultant focusing on infections in stem cell transplant recipients at the Experimental Transplantation and Immunology Branch. He became Chief of the Infectious Diseases Consult Service of the NIH Clinical Center in 2005, and he held this position until July of 2017, when he joined the Infectious Diseases Division of the Mayo Clinic Hospital in Phoenix, AZ. After becoming Consultant and Professor of Medicine at Mayo Medical School, he returned to the NIH in April of 2021 as a member of the Clinical Research Division (Special Projects) of the National Institute of Allergy and Infectious Diseases, and as Staff Clinician in the Transplant Infectious Diseases Consult Service.
- 1 - Delineate algorithms for evaluation of potential kidney transplant recipients and donors
- 2 - Pretransplant histocompatibility testing algorithm: Laboratory and clinical approach
- 3 - Discuss the immunologic basis for acute and chronic rejection of renal allografts
- 4 - Discuss basic pharmacology of currently available immunosuppressive drugs
- 5 - Define the short and long term outcomes of kidney transplant recipients in the modern era
- 6 - Define the short and long term outcomes of kidney transplant donors in the modern era
- 7 - Discuss the pathophysiology and management of common short long-term complications of kidney transplantation: BK and CMV
- 8 - Discuss the pathophysiology and management of common short long-term complications of kidney transplantation: post transplant TB, fungal infections, and bacterial infections (especially UTI)
DocMode acknowledges that no educational grants were received for the creation of this Internet Enduring activity.
Certification of Participation
Provided by: Mayo Clinic
Live Lecture FAQs
Firefox, Chrome, Safari and Internet Explorer
We generally encourage the use of, and fully support only, the latest version.